Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
IVERIC bio, Inc. ISEE
$37.48
+$0.12 (0.31%)
На 18:01, 12 мая 2023
-12.62%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
5139957600.00000000
-
week52high
38.25
-
week52low
8.85
-
Revenue
0
-
P/E TTM
-27
-
Beta
1.09826900
-
EPS
-1.50000000
-
Last Dividend
0.00000000
-
Next Earnings Date
24 июл 2023 г. в 12:30
Описание компании
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Buy | 02 авг 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 07 июл 2022 г. |
| Guggenheim | Buy | 08 июн 2022 г. | |
| B of A Securities | Buy | 08 июн 2022 г. | |
| B. Riley Securities | Neutral | 12 мая 2022 г. | |
| Stifel | Buy | Buy | 08 сент 2022 г. |
| Guggenheim | Buy | Buy | 07 сент 2022 г. |
| Baird | Outperform | Outperform | 07 сент 2022 г. |
| B. Riley Securities | Sell | Neutral | 06 сент 2022 г. |
| Jefferies | Hold | Buy | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Westby Keith | D | 46354 | 20000 | 02 февр 2023 г. |
| Westby Keith | D | 66354 | 20000 | 01 февр 2023 г. |
| Simms Christopher Paul | D | 32429 | 2368 | 03 янв 2023 г. |
| Carroll David Francis | D | 68472 | 3602 | 03 янв 2023 г. |
| SBLENDORIO GLENN | D | 228191 | 17447 | 03 янв 2023 г. |
| Westby Keith | D | 86354 | 3480 | 03 янв 2023 г. |
| Dugel Pravin | D | 37500 | 12500 | 02 янв 2023 г. |
| Dugel Pravin | A | 148723 | 12500 | 02 янв 2023 г. |
| Simms Christopher Paul | D | 18750 | 6250 | 02 янв 2023 г. |
| Simms Christopher Paul | A | 34797 | 6250 | 02 янв 2023 г. |
Новостная лента
Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval
Bloomberg Markets and Finance
01 мая 2023 г. в 20:58
Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, for about $5.9 billion. He also talks about Astellas Pharma's growth strategy with Shery Ahn and Haidi Stroud-Watts on "Bloomberg Daybreak: Asia.
Iveric Bio stock surges on Astellas Pharma takeover deal
Proactive Investors
01 мая 2023 г. в 15:13
Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion. Iveric's primary asset is avacincaptad pegol (ACP) which is currently in trials for treating geographic atrophy, the advanced stage of macular degeneration, a common cause of vision loss in the elderly.
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Investors Business Daily
01 мая 2023 г. в 10:01
Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma appeared first on Investor's Business Daily.
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
Barrons
01 мая 2023 г. в 06:00
Japan's Astellas agrees to pay $40 a share for Iveric, citing the potential of the biopharmaceutical company's ophthalmology programs.
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
Market Watch
01 мая 2023 г. в 01:34
Astellas Pharma Inc. said Monday that it agreed to acquire Iveric bio Inc. for about $5.9 billion to strengthen its capabilities in the ophthalmology field.